Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Cytokinetics Inc (NASDAQ: CYTK) closed the day trading at $51.09 down -1.64% from the previous closing price of $51.94. In other words, the price has decreased by -$1.64 from its previous closing price. On the day, 1.94 million shares were traded. CYTK stock price reached its highest trading level at $51.8 during the session, while it also had its lowest trading level at $49.67.
Ratios:
For a better understanding of CYTK, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.28 and its Current Ratio is at 9.28.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, RBC Capital Mkts on November 08, 2024, initiated with a Outperform rating and assigned the stock a target price of $80.
On August 13, 2024, Goldman Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $85 to $60.
UBS Downgraded its Buy to Neutral on January 24, 2024, whereas the target price for the stock was revised from $61 to $92.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 18 ’24 when Blum Robert I sold 5,000 shares for $50.55 per share. The transaction valued at 252,750 led to the insider holds 397,456 shares of the business.
ROBERT BLUM bought 5,000 shares of CYTK for $252,728 on Nov 18 ’24. On Nov 12 ’24, another insider, Malik Fady Ibraham, who serves as the EVP Research & Development of the company, sold 6,342 shares for $58.48 each. As a result, the insider received 370,880 and left with 113,878 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CYTK now has a Market Capitalization of 6029335040 and an Enterprise Value of 5925881344. For the stock, the TTM Price-to-Sale (P/S) ratio is 1872.47. Its current Enterprise Value per Revenue stands at 1840.908 whereas that against EBITDA is -11.593.
Stock Price History:
Over the past 52 weeks, CYTK has reached a high of $110.25, while it has fallen to a 52-week low of $30.68. The 50-Day Moving Average of the stock is -5.29%, while the 200-Day Moving Average is calculated to be -14.61%.
Shares Statistics:
Over the past 3-months, CYTK traded about 1.19M shares per day on average, while over the past 10 days, CYTK traded about 1584120 shares per day. A total of 118.01M shares are outstanding, with a floating share count of 113.59M. Insiders hold about 3.75% of the company’s shares, while institutions hold 113.27% stake in the company. Shares short for CYTK as of 1730332800 were 15689835 with a Short Ratio of 13.19, compared to 1727654400 on 17322576. Therefore, it implies a Short% of Shares Outstanding of 15689835 and a Short% of Float of 20.31.
